Taxifolin Attenuates Bacterial Pathogenicity and Thereby Enhances Antibacterial Efficacy in Clinically Relevant Bacteria
- 1Graduate School of Biotechnology, Kyung Hee University, Seocheon, Giheung, Yongin 17104, Gyeonggi-do, Republic of Korea
- 2Major in Bio-Cosmetic Engineering, Division of Convergence Studies, Sungkyul University, 53 Sungkyuldaehak-ro, Manan-gu, Anyang-si 14097, Gyeonggi-do, Republic of Korea
Abstract
Biofilm formation is an important pathogenic process that contributes to bacterial virulence, persistence, and reduced susceptibility to antimicrobial treatment. Therefore, taxifolin was evaluated as a potential antibiofilm agent. Taxifolin was assessed for its effects on biofilm formation, planktonic growth, antibiotic susceptibility, and the expression of biofilm- and virulence-associated genes. Taxifolin inhibited biofilm formation by Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Streptococcus mutans, Streptococcus sobrinus, Staphylococcus aureus, Pseudomonas aeruginosa, Cutibacterium acnes, and Porphyromonas gingivalis (IC50, 0.065~0.79 µg/mL). In E. faecalis and E. faecium, taxifolin did not substantially affect planktonic growth at 10 µg/mL. Taxifolin enhanced the antibacterial activity of commercially available antibiotics, and downregulated the expression of cytolysin-associated genes (cylR, cylM, and cylLs), quorum-sensing genes (fsrB and fsrC), biofilm-associated genes (gelE, acm, scm, ebpA, ebpB and bps), and the biofilm-associated virulence gene Esp. Taxifolin inhibited biofilm formation, enhanced bacterial susceptibility, and attenuated virulence-associated gene expression, supporting its potential as an adjunctive antibiofilm therapy for the management of biofilm-associated bacterial infections. Further studies are required to define its mechanism of action, activity against established biofilms, pharmacological properties, safety, and efficacy in appropriate in vivo models.
Related
- Genome mining, antibacterial activity, and metabolomic profiling reveal the biosynthetic potential of Burkholderia glumae isolates from Thailand with activity against clinically important bacterial pathogens
- SERS-CBP: A Comprehensive SERS Spectral Database of Clinically Important Bacterial Pathogens.
- Isolation, Identification, and Pathogenicity of Aeromonas veronii from Diseased Paracobitis variegatus
- Major effector loss reveals compensatory pathogenicity networks in a necrotrophic wheat pathogen
- Conserved water molecules shape the pathogenicity of missense variants in human proteins
BibTeX
@article{yoon2026taxifolin,
title = {{Taxifolin Attenuates Bacterial Pathogenicity and Thereby Enhances Antibacterial Efficacy in Clinically Relevant Bacteria}},
author = {Ji-Hyun Yoon and Yeo-Jin Kim and Ki-Young Kim},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219469},
url = {https://www.mdpi.com/1422-0067/27/21/9469},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Taxifolin Attenuates Bacterial Pathogenicity and Thereby Enhances Antibacterial Efficacy in Clinically Relevant Bacteria
AU - Ji-Hyun Yoon
AU - Yeo-Jin Kim
AU - Ki-Young Kim
PY - 2026
DA - 2026/10/23
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219469
UR - https://www.mdpi.com/1422-0067/27/21/9469
AB - Biofilm formation is an important pathogenic process that contributes to bacterial virulence, persistence, and reduced susceptibility to antimicrobial treatment. Therefore, taxifolin was evaluated as a potential antibiofilm agent. Taxifolin was assessed for its effects on biofilm formation, planktonic growth, antibiotic susceptibility, and the expression of biofilm- and virulence-associated genes. Taxifolin inhibited biofilm formation by Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Streptococcus mutans, Streptococcus sobrinus, Staphylococcus aureus, Pseudomonas aeruginosa, Cutibacterium acnes, and Porphyromonas gingivalis (IC50, 0.065~0.79 µg/mL). In E. faecalis and E. faecium, taxifolin did not substantially affect planktonic growth at 10 µg/mL. Taxifolin enhanced the antibacterial activity of commercially available antibiotics, and downregulated the expression of cytolysin-associated genes (cylR, cylM, and cylLs), quorum-sensing genes (fsrB and fsrC), biofilm-associated genes (gelE, acm, scm, ebpA, ebpB and bps), and the biofilm-associated virulence gene Esp. Taxifolin inhibited biofilm formation, enhanced bacterial susceptibility, and attenuated virulence-associated gene expression, supporting its potential as an adjunctive antibiofilm therapy for the management of biofilm-associated bacterial infections. Further studies are required to define its mechanism of action, activity against established biofilms, pharmacological properties, safety, and efficacy in appropriate in vivo models.
SN - 1422-0067
ER -